BE 101
Alternative Names: BE-101Latest Information Update: 05 Nov 2024
Price :
$50 *
At a glance
- Originator Be Biopharma
- Class Antihaemorrhagics; Cell therapies; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia B